A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross

The antineoplastic drug bleomycin leads to the side effect of pulmonary fibrosis in both humans and mice. We challenged genetically diverse inbred lines of mice from the Collaborative Cross with bleomycin to determine the heritability of this phenotype. Sibling pairs of mice from 40 lines were treated with bleomycin. Lung disease was assessed by scoring lung pathology and by measuring soluble collagen levels in lavage fluid. Serum micro ribonucleic acids (miRNAs) were also measured. Inbred sibling pairs of animals demonstrated high coinheritance of the phenotypes of disease susceptibility or disease resistance. The plasma levels of one miRNA were clearly correlated in sibling mice. The results showed that, as in humans, the lines that comprise the Collaborative Cross exhibited wide genetic variation in response to this drug. This finding suggests that the genetically diverse Collaborative Cross animals may reveal drug effects that might be missed if a study were based on a conventional mouse strain.

[1]  David Galas,et al.  Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes , 2011, BMC Medical Genomics.

[2]  Oliver Eickelberg,et al.  Inhibition and role of let-7d in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[3]  K. Isobe,et al.  Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. , 2009, The Journal of investigative dermatology.

[4]  K. Isobe,et al.  Injection of bleomycin in newborn mice induces autoimmune sialitis that is transferred by CD4 T cells , 2009, Immunology and cell biology.

[5]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[6]  M. Fujimoto,et al.  CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. , 2008, Arthritis and rheumatism.

[7]  Elissa J. Chesler,et al.  The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics , 2008, Mammalian Genome.

[8]  M. Fujimoto,et al.  Immunopathology and Infectious Disease CD 19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma , 2010 .

[9]  Wei Wang,et al.  The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics , 2007, Mammalian Genome.

[10]  G. Hunninghake,et al.  Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. , 2007, American journal of respiratory and critical care medicine.

[11]  A. Lemay,et al.  Bleomycin-induced pulmonary fibrosis susceptibility genes in AcB/BcA recombinant congenic mice. , 2005, Physiological genomics.

[12]  Nengjun Yi,et al.  The Collaborative Cross, a community resource for the genetic analysis of complex traits , 2004, Nature Genetics.

[13]  C. Amos,et al.  Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. , 2002, Human molecular genetics.

[14]  C. Baecher-Allan,et al.  Mapping susceptibility genes for the induction of pulmonary fibrosis in mice. , 2002, Chest.

[15]  S. Sleijfer.  Bleomycin-induced pneumonitis. , 2001, Chest.

[16]  D. D'cruz.  Autoimmune diseases associated with drugs, chemicals and environmental factors. , 2000, Toxicology letters.

[17]  S. Kaye,et al.  Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. , 1998, British Journal of Cancer.

[18]  S. Kaye,et al.  The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Lazo,et al.  The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents. , 1990, Cancer treatment reviews.

[20]  Katsutoshi Takahashi,et al.  Different Sensitivity to Bleomycin-Induced Pulmonary Fibrosis among Various Strains of Mice , 1987 .

[21]  S. Phan,et al.  The role of strain variation in murine bleomycin-induced pulmonary fibrosis. , 2015, The American review of respiratory disease.